AstraZeneca (AZN.L) stock price, revenue, and financials

AstraZeneca market cap is £109.5 b, and annual revenue was $24.38 b in FY 2019

£109.5 B

AZN.L Mkt cap, 11-Jun-2021

$6.6 B

AstraZeneca Revenue Q3, 2020
AstraZeneca Gross profit (Q3, 2020)5.2 B
AstraZeneca Gross profit margin (Q3, 2020), %79.2%
AstraZeneca Net income (Q3, 2020)651 M
AstraZeneca EBIT (Q3, 2020)1.2 B
AstraZeneca Cash, 30-Sept-20208.1 B
AstraZeneca EV123.7 B

AstraZeneca Revenue

AstraZeneca revenue was $24.38 b in FY, 2019 which is a 10.4% year over year increase from the previous period.

Embed Graph

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

AstraZeneca Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

22.5b22.1b24.4b

Revenue growth, %

(2%)(2%)10%

Cost of goods sold

4.3b4.9b4.9b

Gross profit

18.1b17.2b19.5b

Gross profit Margin, %

81%78%80%

Sales and marketing expense

310.0m331.0m339.0m

R&D expense

5.8b5.9b6.1b

General and administrative expense

10.2b10.0b11.7b

Operating expense total

16.3b16.3b18.1b

EBIT

3.7b3.4b2.9b

EBIT margin, %

16%15%12%

Interest expense

664.0m741.0m772.0m

Interest income

70.0m96.0m123.0m

Pre tax profit

2.2b2.0b1.5b

Income tax expense

(641.0m)(57.0m)321.0m

Net Income

2.9b2.1b1.2b

EPS

2.41.71.0

AstraZeneca Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

3.3b4.8b5.4b

Accounts Receivable

2.8b3.0b3.6b

Inventories

3.0b2.9b3.2b

Current Assets

13.2b15.6b15.6b

PP&E

7.6b7.4b7.7b

Goodwill

11.8b11.7b11.7b

Total Assets

63.4b60.7b61.4b

Accounts Payable

3.6b1.7b1.8b

Short-term debt

2.2b1.8b2.0b

Current Liabilities

16.4b16.3b18.1b

Long-term debt

15.6b17.4b16.2b

Non-Current Liabilities

30.3b30.3b28.7b

Total Debt

17.8b19.1b18.2b

Total Liabilities

46.7b46.6b46.8b

Common Stock

317.0m317.0m328.0m

Additional Paid-in Capital

4.4b4.4b7.9b

Retained Earnings

8.2b5.7b2.8b

Total Equity

16.6b14.0b14.6b

Debt to Equity Ratio

1.1 x1.4 x1.2 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x

Financial Leverage

3.8 x4.3 x4.2 x

AstraZeneca Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

2.9b2.1b1.2b

Depreciation and Amortization

3.0b3.8b3.8b

Accounts Receivable

83.0m(523.0m)(898.0m)

Inventories

(548.0m)(13.0m)(316.0m)

Accounts Payable

415.0m(103.0m)868.0m

Cash From Operating Activities

3.6b2.6b3.0b

Purchases of PP&E

(1.3b)(1.0b)(979.0m)

Cash From Investing Activities

(2.3b)963.0m(657.0m)

Short-term Borrowings

336.0m(98.0m)(516.0m)

Long-term Borrowings

(1.8b)(1.4b)(1.7b)

Dividends Paid

(3.5b)(3.5b)(3.6b)

Cash From Financing Activities

(2.9b)(2.0b)(1.8b)

Net Change in Cash

(1.7b)1.5b547.0m

Interest Paid

698.0m676.0m774.0m

Income Taxes Paid

454.0m537.0m1.1b

AstraZeneca Ratios

USDQ1, 2017

Debt/Equity

1.2 x

Debt/Assets

0.3 x

Financial Leverage

4.1 x

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020Q4, 2020FY, 2020

Projects in R&D Pipeline

99133146132144149167171

Phase I Trials Projects

3324444150383435

Phase II Trials Projects

2711333637435042

Phase III Trials Projects

1911352723222725

Life-cycle Management Projects

34465669

Blood Pressure Screenings (Africa)

5.7 m9.97 m13.5 m16.7 m

New Phase I Projects

5343111553355

New Phase II Projects

23412145514388

New Pivotal Study Projects

215666315688

New Projects to Registration

3131551322

NME Phase I (Oncology)

21191817262621212018182019202121

NME Phase II (Oncology)

341010202025222527272524252121

NME in Late-stage Development (Oncology)

54441111141714121279101010

NME Phase I (Biopharmaceuticals)

13121213131313131416161716171414

NME Phase II (Biopharmaceuticals)

18171717232322222122222021212121

NME in Late-stage Development (Biopharmaceuticals)

4432333355546555

Healthcare Workers Trained

10.82 k35.89 k81.61 k132.25 k

People Reached (Healthcare Programmes)

7.17 m12.01 m16.42 m25.03 m

People Reached (Patient Assistance Programmes)

9 m9.3 m9.7 m10.1 m

NME Phase I

34263227

NME Phase II

20253936

NME in Late-stage Development

118810

Countries

100100100100

Health Facilities Activated

8272 k2.62 k3.36 k

Patients Included in Clinical Trials

33 k

Scientific Collaborations

600630730800

Young Health Programme Members

2.25 m3.01 m4.01 m

AstraZeneca Sustainability Metrics

 FY, 2020

Сorporate Сontributions

20.4 m

Working Days Lost per Year due to Accidents

46.41

Water Used

3.44 m cubic meters

Wastewater Chemical Oxygen Demand

343 metric tons

Waste Recycled

12.15 k metric tons

Waste Generated

30.26 k metric tons

Volunteer Hours

28.44 k

Total Recordable Incident Rate

0.63

Total Greenhouse Gas Emissions

8.05 m metric tons of carbon dioxide equivalent

Solvent Volatile Organic Compound Emissions

199 metric tons of carbon dioxide equivalent

Solvent Volatile Organic Compound Consumptions

3.58 k metric tons of carbon dioxide equivalent

Nonhazardous Waste Generated

19.76 k metric tons

Lost Time Incident Rate (Employees)

0.42

Lost Time Incident Rate (Construction Contractors)

1.48

Hazardous Waste Generated

10.5 k metric tons

Greenhouse Gas Emissions (Scope 3, Waste Generated in Operations)

24.9 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Use of Sold Products)

978.9 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Upstream Transportation and Distribution)

247.96 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Upstream Leased Assets)

46.06 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Purchased Goods and Services)

5.77 m metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Fuel and Energy-Related Activities)

50.36 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, End-of-Life Treatment of Sold Products)

72.07 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Employee Commuting)

35.21 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Downstream Transportation and Distribution)

377.77 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Downstream Leased Assets)

5.95 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Capital Goods)

116.06 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3, Business Travel)

80.8 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 3)

7.8 m metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 2, Market-Based)

23.24 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

224.77 k metric tons of carbon dioxide equivalent

Energy Used (Renewables)

674.02 k MWh

Energy Used (Power and Heat Renewables)

5.26 k MWh

Energy Used (Imported Renewables)

668.76 k MWh

Energy Used

1.6 m MWh

AstraZeneca Human Capital

FY, 2019FY, 2018FY, 2017
Male, percent10%10%10%
Male (Senior and Middle Management), percent10.9%11.1%11.1%
Female (Senior and Middle Management), percent9.1%8.9%8.9%
Female (Management), percent8.3%8.3%8.1%
Female (Executive Leadership), percent6.4%6%5.6%
Male (Executive Leadership), percent13.6%14%14.4%
Female (Board), percent6.7%8.4%8.4%
Male (Board), percent13.3%11.6%11.6%
Male (Management), percent11.7%11.7%11.9%
Female, percent10%10%10%

AstraZeneca Employee Rating

4.24212 votes
Culture & Values
4.1
Work/Life Balance
3.9
Senior Management
3.7
Salary & Benefits
4.1
Career Opportunities
3.8
Source